HRS-4139
/ Jiangsu Hengrui Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
September 26, 2026
A Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of HRS-4139 in Healthy Participants
(clinicaltrials.gov)
- P1 | N=40 | Recruiting | Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting
Enrollment open • Dermatology • Immunology • Psoriasis
September 04, 2026
A Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of HRS-4139 in Healthy Participants
(clinicaltrials.gov)
- P1 | N=40 | Not yet recruiting | Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.
New P1 trial • Dermatology • Immunology • Psoriasis
1 to 2
Of
2
Go to page
1